scholarly journals Skeletal muscle loss in the postoperative acute phase after esophageal cancer surgery as a new prognostic factor

2020 ◽  
Author(s):  
Naoaki Maeda ◽  
Yasuhiro Shirakawa ◽  
Shunsuke Tanabe ◽  
Kazufumi Sakurama ◽  
Kazuhiro Noma ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Survival Rate ◽  
Acute Phase ◽  
Psoas Muscle ◽  
Muscle Loss ◽  
Psoas Major Muscle ◽  
Significant Difference ◽  
Skeletal Muscle Loss ◽  
Long Term Prognosis

Abstract Background: The postoperative survival rate of patients with esophageal squamous cell carcinoma (ESCC) remains poor compared with other gastrointestinal cancers. We hypothesized that skeletal muscle loss (SML) in the postoperative acute phase might be a new predictor for long-term prognosis after highly invasive surgery such as ESCC surgery.Methods: The following items were retrospectively investigated. First, whether SML occurred in the postoperative acute phase of ESCC was verified. Second, the preoperative and intraoperative factors involved in SML in the postoperative acute phase of ESCC were investigated. Then, whether SML in the postoperative acute phase affected long-term prognosis was examined. The medical records of consecutive patients who underwent radical esophagectomy for ESCC were retrospectively reviewed; 72 cases were eligible for this study.Results: There was already a significant difference between the total psoas major muscle mass index (TPI) of the acute phase up to 3 days after surgery and the preoperative baseline TPI. The psoas muscle loss index (PMLI) was significantly milder in cases with less blood loss during surgery and in cases that underwent thoracoscopic esophagectomy than in cases that underwent open esophagectomy. The three-year overall survival rate was significantly different between the PMLI severe group and the PMLI mild group.Conclusion: SML occurred even in the postoperative acute phase. Furthermore, it is very significant that SML in the postoperative acute phase of ESCC surgery is involved in the long-term prognosis.

scholarly journals Skeletal muscle loss in the postoperative acute phase after esophageal cancer surgery as a new prognostic factor

2020 ◽  
Author(s):  
Naoaki Maeda ◽  
Yasuhiro Shirakawa ◽  
Shunsuke Tanabe ◽  
Kazufumi Sakurama ◽  
Kazuhiro Noma ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Survival Rate ◽  
Acute Phase ◽  
Reduction Rate ◽  
Lumbar Vertebra ◽  
Muscle Loss ◽  
Psoas Major Muscle ◽  
Skeletal Muscle Loss ◽  
Long Term Prognosis

Abstract Background: The postoperative survival rate of patients with esophageal squamous cell carcinoma (ESCC) remains poor compared with other gastrointestinal cancers. We hypothesized that skeletal muscle loss in the postoperative acute phase might be a new predictor for long-term prognosis after highly invasive surgery such as ESCC surgery.Methods: The following items were retrospectively investigated. First, whether skeletal muscle loss occurred in the postoperative acute phase of ESCC was verified. Second, the preoperative and intraoperative factors involved in skeletal muscle loss in the postoperative acute phase of ESCC were investigated. Then, whether skeletal muscle loss in the postoperative acute phase affected long-term prognosis was examined. The medical records of consecutive patients who underwent radical esophagectomy for ESCC between January 2010 and June 2015 were retrospectively reviewed; 72 cases were eligible for this study. The total psoas major muscle mass index (TPI) at the level of the third lumbar vertebra (L3) was measured using computed tomography (CT) before surgery and three days after surgery. The long-term prognosis was estimated by the Kaplan-Meier method and the multivariate logistic regression model.Results: There was already a significant reduction of TPI in the acute phase up to POD 3 after ESCC surgery in comparison with the preoperative baseline TPI (P < 0.001). The TPI reduction rate was significantly milder in cases with less blood loss during surgery and in cases that underwent thoracoscopic esophagectomy than in cases that underwent open esophagectomy. The three-year overall survival rate was significantly different between the TPI reduction rate severe group and the TPI reduction rate mild group.Conclusion: skeletal muscle loss occurred even in the postoperative acute phase. Furthermore, it is very significant that skeletal muscle loss in the postoperative acute phase of ESCC surgery is involved in the long-term prognosis.

scholarly journals Skeletal muscle loss in the postoperative acute phase after esophageal cancer surgery as a new prognostic factor

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Naoaki Maeda ◽  
Yasuhiro Shirakawa ◽  
Shunsuke Tanabe ◽  
Kazufumi Sakurama ◽  
Kazuhiro Noma ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Esophageal Cancer ◽  
Prognostic Factor ◽  
Acute Phase ◽  
Cancer Surgery ◽  
Muscle Loss ◽  
Esophageal Cancer Surgery ◽  
Skeletal Muscle Loss

The impact of skeletal muscle loss for hepatocellular carcinoma treated with lenvatinib.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 493-493
Author(s):  
Mao Okada ◽  
Hiroyuki Nakanishi ◽  
Masayuki Kurosaki ◽  
Kento Inada ◽  
Sakura Kirino ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skeletal Muscle ◽  
Dose Intensity ◽  
Muscle Loss ◽  
Muscle Area ◽  
Chronological Change ◽  
Significant Difference ◽  
Skeletal Muscle Loss ◽  
Tki Treatment ◽  
The Impact

493 Background: Many previous reports have shown that skeletal muscle loss (SML) is one of the prognostic factors for hepatocellular carcinoma (HCC) patients treated with sorafenib. However, there are few reports about the impact of SML for the HCC patients treated with lenvatinib. Therefore, we evaluated the relation between SML and overall survival (OS) of HCC patients treated with lenvatinib (LEN). Methods: We retrospectively analyzed 50 HCC patients treated with LEN from April 2018 to February 2019. We included 36 patients who continued LEN more than 8 weeks and evaluated CT scans before treatment and after 8 weeks. Skeletal muscle area was measured on axial image at the level of the third lumber vertebra (L3) using sliceOmatic. Skeletal Mass Index (SMI) was calculated by dividing the muscle area (㎠) with square of height (㎡). The definition of myopenia is based on the guideline described by the Japan Society of Hepatology (42㎠/㎡ in men and 38 ㎠/㎡ in women). ΔSMI is a chronological change of SMI for 8 weeks. We calculated decreasing rate of ΔSMI. We evaluated the relation between chronological change of SMI and OS. Results: The patients with myopenia at baseline were 12 (33.3 %). The decreasing rate of ΔSMI at 8 weeks was -2.57 % [-5.9, 0.2]. SMI had decreased in 27 patients (75 %) for 8 weeks. There was no significant difference between OS and baseline myopenia (p = 0.2), ALBI grade (p = 0.2), BCLC stage (p = 0.5), up to 7 in or out (p = 0.35), previous TKI treatment (p = 0.15), metastasis (p = 0.91), or vascular invasion (p = 0.12). However, the patients who had decreased SMI had significantly poor prognosis (p = 0.028). In backgrounds, there was no significant difference between patients with or without decreasing of ΔSMI, such as baseline myopenia (p = 0.7), ALBI grade (p = 0.4), BCLC stage (p = 1.0), Child Pugh score (p = 0.8), age (p = 0.6), sex (p = 0.3), up to7 in or out (p = 1.0), previous TKI treatment (p = 0.3), and relative dose intensity at 4 weeks (p = 0.9). Conclusions: There was no significant correlation between baseline myopenia and OS. However, chronological decreasing of SMI for 8 weeks was a prognostic factor of HCC patients treated with LEN. Therefore, monitoring and preventing of decreasing of skeletal muscle mass may be important.

Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy

Surgery Today ◽  
2019 ◽  
Vol 49 (12) ◽  
pp. 1022-1028 ◽  
Author(s):  
Naoki Kamitani ◽  
Kazuhiro Migita ◽  
Sohei Matsumoto ◽  
Kohei Wakatsuki ◽  
Tomohiro Kunishige ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Esophageal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Long Term Outcomes ◽  
Skeletal Muscle Loss

scholarly journals Nutritional Approach to Cancer Cachexia: A Proposal for Dietitians

Nutrients ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 345
Author(s):  
Kotone Tanaka ◽  
Sho Nakamura ◽  
Hiroto Narimatsu
Keyword(s):  
Skeletal Muscle ◽  
Nutritional Support ◽  
Skeletal Muscle Mass ◽  
Cancer Cachexia ◽  
The Body ◽  
Current Evidence ◽  
Muscle Loss ◽  
Related Factors ◽  
Skeletal Muscle Loss

Cachexia is one of the most common, related factors of malnutrition in cancer patients. Cancer cachexia is a multifactorial syndrome characterized by persistent loss of skeletal muscle mass and fat mass, resulting in irreversible and progressive functional impairment. The skeletal muscle loss cannot be reversed by conventional nutritional support, and a combination of anti-inflammatory agents and other nutrients is recommended. In this review, we reviewed the effects of nutrients that are expected to combat muscle loss caused by cancer cachexia (eicosapentaenoic acid, β-hydroxy-β-methylbutyrate, creatine, and carnitine) to propose nutritional approaches that can be taken at present. Current evidence is based on the intake of nutrients as supplements; however, the long-term and continuous intake of nutrients as food has the potential to be useful for the body. Therefore, in addition to conventional nutritional support, we believe that it is important for the dietitian to work with the clinical team to first fully assess the patient’s condition and then to safely incorporate nutrients that are expected to have specific functions for cancer cachexia from foods and supplements.

P6461The long-term clinical comparisons of symptomatic patients of pulmonary embolism with and those without deep vein thrombosis: from the COMMAND VTE Registry

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
K Murata ◽  
Y Yamashita ◽  
T Morimoto ◽  
H Amano ◽  
T Takase ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Acute Phase ◽  
Clinical Presentation ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
Severe Clinical Presentation ◽  
Recurrent Vte ◽  
Deep Vein

Abstract Background Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), has significant morbidity and mortality. Acute PE, in particular, is fatal if we miss it, and symptomatic patients of PE sometimes have concomitant DVT. Purpose This study compared the risk of mortality in symptomatic patients of PE with and those without DVT in the long term. Methods The COMMAND VTE Registry is a multicenter registry enrolling consecutive 3027 patients with acute symptomatic VTE objectively confirmed by imaging examination or by autopsy among 29 centers in Japan between January 2010 and August 2014. Patients with both PE and DVT (N=1334) were regarded as PE patients, and the current study population consisted of 1715 PE patients and 1312 DVT patients. Results There were 1203 symptomatic patients of PE, including 381 without and 822 with DVT. In our cohort, the mean age was 67.9±14.9 years, 63% was female, 44% had hypertension, 12% diabetes mellitus, 5% history of VTE. There were 20% of active cancer. Baseline characteristics were well matched except for dyslipidemia (18% vs. 23%, p=0.021) and atrial fibrillation (8% vs. 5%, p=0.045). Patients without DVT had a more severe clinical presentation compared to those with DVT, including hypoxemia, shock and arrest. Moreover, Initial parenteral anticoagulation therapy in the acute phase was administered less frequently in patients without DVT (89% vs. 96%, P=0.0001). Two groups received thrombolysis (20% vs. 26%, P=0.18) and mechanical supports (Ventilator 14% vs. 5%, p<0.001, PCPS 5% vs. 3%, p<0.001, respectively). During follow-up, 93 (8%) patients experienced recurrent VTE events and 98 (8%) major bleeding events, and 323 (27%) patients died. The most frequent cause of death was cancer (11%). There were a significant differences in the cumulative incidences of all-cause death between the groups (32% vs. 24%, P=0.006), whereas there was significant difference in VTE-related death (13% vs. 4%, p<0.001). Estimated freedom rates from death for patients of PE without and those with DVT were as follows: 88% vs 99% at 10-day, 86% vs 95% at 1-month, 75% vs 83% at 1-year, and 64% vs 71% at 5-year, respectively. Landmark analysis Conclusions In symptomatic patients of PE, there was a difference in mortality between groups, but no difference in recurrent VTE. Patients without DVT had a more severe clinical presentation compared to those with DVT, and many VTE-related deaths in the acute phase. The one-month mortality rate differed statistically between groups, but there was no significant difference in long-term survival beyond one month. Most of deaths were due to underlying diseases, mainly cancer, and less commonly due to VTE in the long term. Acknowledgement/Funding Research Institute for Production Development, Mitsubishi Tanabe Pharma Corporation

Time course of skeletal muscle loss and oxidative stress in rats with walker 256 solid tumor

2010 ◽  
Vol 42 (6) ◽  
pp. 950-958 ◽  
Author(s):  
Flávia A. Guarnier ◽  
Alessandra L. Cecchini ◽  
Andréia A. Suzukawa ◽  
Ana Leticia G.C. Maragno ◽  
Andréa N.C. Simão ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Skeletal Muscle ◽  
Solid Tumor ◽  
Time Course ◽  
Muscle Loss ◽  
Skeletal Muscle Loss ◽  
Walker 256 ◽  
And Oxidative Stress

Skeletal muscle loss and prognosis of breast cancer patients

2017 ◽  
Vol 25 (7) ◽  
pp. 2221-2227 ◽  
Author(s):  
Yoshiko Kubo ◽  
Tateaki Naito ◽  
Keita Mori ◽  
Gakuji Osawa ◽  
Etsuko Aruga
Keyword(s):  
Breast Cancer ◽  
Skeletal Muscle ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Breast Cancer Patients ◽  
Skeletal Muscle Loss
Sign in / Sign up

Export Citation Format

Share Document